bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
2.860
+0.200 (7.52%)
Oct 14, 2025, 3:37 PM EDT - Market open
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.27M in the quarter ending June 30, 2025, a decrease of -47.05%. This brings the company's revenue in the last twelve months to $7.68M, up 4.99% year-over-year. In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth.
Revenue (ttm)
$7.68M
Revenue Growth
+4.99%
P/S Ratio
0.19
Revenue / Employee
$134,755
Employees
57
Market Cap
12.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
Dec 31, 2022 | 4.80K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BIAF News
- 5 days ago - WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 5 days ago - bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Business Wire
- 5 days ago - WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 6 days ago - bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules - Business Wire
- 7 days ago - bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 - Business Wire
- 14 days ago - WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m - PRNewsWire
- 14 days ago - bioAffinity Technologies Announces Closing of $4.8 Million Public Offering - Business Wire
- 14 days ago - WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m - PRNewsWire